Announced positive topline data from Phase 1 driving simulation trial of GlyphAllo™, showing that GlyphAllo did not impair ...
Roche announced today the U.S. Food and Drug Administration (FDA) 510(k) clearance of the cobas® eplex respiratory pathogen ...
Single-use device prepares motile sperm for IVF, ICSI and IUI, giving fertility labs the next evolution in sperm separation ...
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a ...
Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm for its multiple myeloma and ...
(Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule ...
Low list price is designed to reduce out-of-pocket costs for insured patients, including Medicare beneficiaries. Autoinjector ...
September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties. Includes increase in related party accounts ...
About Yarrow Bioscience Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing ...
After a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec ...
About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the ...
Two-year agreement and approximately US$198,000 in potential purchases while opening established UK first-aid, medical-supply ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results